Neoadjuvant HAIC of TACE Plus Donafenib in BCLC B Stage HCC: a Multi-center Randomized Controlled Trial.
Status:
Not yet recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of the combination therapy
with HAIC-TACE and donafenib compared to TACE plus donafenib in patients with BCLC B stage
unresectable hepatocellular carcinoma (HCC) out of up-to-seven criteria.